9:00-10:30

Moderator: Kjeld Møller Pedersen PhD, Professor of Health Economics and Health Policy Department of Public Health, Health Economics, University of Southern Denmark, Odense C, Denmark

This session is a debate between Prof. Glasziou and Prof. Kristiansen addressing four issues surrounding Evidence-Based Medicine: 1) EBM is primarily a method for clinical decisions, not for health policy; 2) The superiority of RCT and MA is based on a dogma, not scientific proof; 3) The Cochrane collaboration is an anti-industry movement; and 4) There is no evidence that EBM improves people’s health.
 

9:00-9:10

9:10-9:40

9:40-10:10

10:10-10:30

10:30-10:45

10:45-11:45

DB1
RATES AND RISKS OF STARTING INSULIN IN DIABETES MELLITUS TYPE-2 PATIENTS
Sturkenboom MC¹, Dieleman JP², Van der Lei J^2
1Erasmus University Medical Center, Soest, The Netherlands, ²Erasmus University Medical Center, Rotterdam, The Netherlands

DB2
INSULIN THERAPY AMONG TYPE 2 DIABETES PATIENTS : IMPACT OF CONVERSION TO A PEN DEVICE ON ADHERENCE, HYPOGLYCEMIC EVENTS, AND COSTS
Lee WC¹, Balu S², Cobden D³, Joshi AV³, Pashos CL^2
1Abt Associates Inc, Bethesda, MD, USA, ²Abt Associates Inc, Lexington, MA, USA, ³Novo Nordisk Inc, Princeton, NJ, USA

DB3
GLYCEMIC RESPONSE TO NEWLY INITIATED ANTIHYPERGLYCEMIC THERAPIES IN A LARGE MANAGED CARE ORGANIZATION
Karter AJ, Moffet HH, Ahmed AT, Liu JY, Go AS, Selby JV
Kaiser Permanente, Oakland, CA, USA

DB4
SELF MONITORING OF BLOOD GLUCOSE IN PATIENTS WITH TYPE 2 DIABETES: COST UTILITY ANALYSIS IN A UNITED STATES THIRD-PARTY PAYER SETTING
Palmer AJ¹, Minshall ME², Valentine WJ¹, Foos V¹, Tunis SL^2
1IMS, Allschwil, Switzerland, ²IMS, Fishers, IN, USA

Economic Studies I

ES1
COST-UTILITY ANALYSES OF NEW MEDICAL TECHNOLOGIES: OFTEN COST-EFFECTIVE, SOMETIMES COST-INEFFECTIVE, DOMINANT, OR DOMINATED, BUT ALMOST NEVER “DECREMENTALLY” COST-EFFECTIVE.
Kent DM¹, Cohen JT¹, Fendrick AM², Langa KM², Neumann PJ^3
1Tufts-New England Medical Center, Boston, MA, USA, ²University of Michigan, Ann Arbor, MI, USA, ³Tufts University School of Medicine, Boston, MA, USA

ES2
DIRECT MEDICAL COSTS OF SOLID ORGAN TRANSPLANT IN BRITISH COLUMBIA, CANADA
Levy AR¹, Sobolev B², James D³, Sullivan SD⁴, Partovi N⁵, Barrable W⁵, Levy R^5
1Oxford Outcomes Ltd, Vancouver, BC, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³St Paul's Hospital, Vancouver, BC, Canada, ⁴University of Washington, Seattle, WA, USA, ⁵BC Transplant Society, Vancouver, BC, Canada

ES3
PROCESS OPTIMIZATION IN A 10-BED INTENSIVE CARE UNIT (ICU) IN GERMANY: IMPACT ON CASE-RELATED TREATMENT COSTS
Brecht JG¹, Mueller K², Welte R³, Schädlich P^4
1InForMed GmbH, Ingolstadt, Bavaria, Germany, ²Sana-Krankenhaus Ruegen, Bergen, Mecklenburg-Vorp, Mecklenburg-Vorp, Germany, 3GlaxoSmithKline, Munich, Germany, 4InForMed GmbH, Itzehoe, Schleswig-Holste, Germany

ES4
SYSTEMATIC REVIEW OF BUDGET IMPACT ANALYSES
Muszbek N, Hutton J
UnitedBioSource Corporation, London, UK

GI Disorders

GI1
COST OF FUNCTIONAL DYSPEPSIA – RESULTS FROM A LARGE US EMPLOYER DATABASE
George S¹, Kleinman N², Brook R³, Smeeding J^4
1Conexus Health, Tampa, FL, USA, ²The HCMS Group, Cheyenne, WY, USA, ³The JeSTARx Group, Newfoundland, NJ, USA, ⁴The JeSTARx Group, Dallas, TX, USA

GI2
DICLOFENAC-ASSOCIATED ULCER RISK IS REDUCED BY PROTON PUMP INHIBITORS: NESTED CASE CONTROL STUDY
Höer A¹, Gothe H¹, Mangiapane S¹, Sterzel A², Grass U³, Häussler B^1
1IGES GmbH, Berlin, Germany, ²ALTANA Pharma GmbH, Konstanz, Germany, ³ALTANA Pharma Deutschland GmbH, Konstanz, Germany

GI3
COST-UTILITY ANALYSIS IN A UK SETTING OF VASOACTIVE DRUG TREATMENTS IN ACUTE BLEEDING OESOPHAGEAL VARICES IN CIRRHOTIC PATIENTS – A DISCRETE EVENT SIMULATION MODEL
Wechowski JG¹, Tetlow AP¹, McEwan P¹, Woehl A¹, Currie CJ^2
1Cardiff Research Consortium, Cardiff, South Glamorgan, UK, ²Cardiff University, Cardiff, South Glamorgan, UK

GI4
COST-EFFECTIVENESS OF TRIPLE THERAPIES OF ESOMEPRAZOLE AND RABEPRAZOLE FOR H. PYLORI ERADICATION IN THE PUBLIC SECTOR OF HONG KONG
Lee KK, Lee VWY, Chan FK
The Chinese University of Hong Kong, Shatin, Hong Kong, China
 

Individual's Health

IH1
PATIENTS' WILLINGNESS TO PAY FOR DIFFERENT CHARACTERISTICS OF THE ATOPIC DERMATITIS TREATMENT
Monzini MS¹, De Portu S², Baranzoni N³, Scalone L¹, Giannetti A³, Mantovani LG^2
1University of Milan, Milan, Milan, Italy, ²University of Naples, Federico II, Naples, Naples, Italy, ³Policlinico Hospital, University of Modena and Reggio Emilia, Modena, Modena, Italy

IH2
HEALTH OUTCOMES FOR MOTHERS OF DISABLED AND CHRONICALLY ILL CHILDREN
Lethbridge L, Burton P, Phipps S
alhousie University, Halifax, NS, Canada

IH3
FEASIBILITY AND PRIMARY VALIDITY OF A GERMAN EQ-5D CHILDREN'S VERSION
Greiner W
Universität Bielefeld, Bielefeld, Germany

IH4
METHYLPHENIDATE PRESCRIPTIONS FOR CHILDREN AND ADOLESCENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD): NEW DATA FROM NORDBADEN/GERMANY
Schlander M¹, Schwarz O¹, Viapiano M², Bonauer N^2
1Institute for Innovation & Valuation in Health Care (InnoVal-HC), Eschborn, Germany, ²Kassenaerztliche Vereinigung Baden-Wuerttemberg, Karlsruhe, Germany

11:45-12:00

CV1
COST-EFFECTIVENESS OF EPTIFIBATIDE IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN GERMANY
Dewilde S¹, Bruggenjurgen B², Welte R³, Willich SN^4
1United BioSource Corporation, Brussels, Belgium, ²Alpha Care, Celle, Germany, ³GlaxoSmithKline, Munich, Germany, ⁴Charite University Medical Center, Berlin, Germany

CV2
RECURRENT INFREQUENT UNEXPLAINED PALPITATIONS (RUP) STUDY: COMPARISON OF IMPLANTABLE LOOP RECORDER VERSUS CONVENTIONAL DIAGNOSTIC TESTING.
Giada F¹, Raviele A¹, Ponzi P², Colangelo I^2
1Umberto I Hospital, Mestre-Venice, Venice, Italy, ²Medtronic Italia, Sesto San Giovanni (MI), Italy

CV3
COST-EFFECTIVENESSS OF INTENSIVE STATIN THERAPY COMPARED TO MODERATE STATIN THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME: ANALYSIS FROM CANADA, GERMANY AND THE UK
Drummond MF¹, Schwartz JS², Koren M³, Cannon C⁴, Davie A⁵, Shui A⁴, Murphy S⁴, Graff J^6
1University of York, York, Heslington, UK, ²University of Pennsylvania, Merion Stn, PA, USA, ³Memorial Hospital, Jacksonville Heart Center, Jacksonville Center for Clinical Research, Jacksonville, FL, USA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, ⁵I3 Innovus, Uxbridge, Middlesex, UK, ⁶Pfizer, Inc, New York, NY, USA

CV4
ASSESSING COST-EFFECTIVENESS BEFORE MARKETING: A CASE-STUDY OF RIMONABANT FOR REDUCTION OF CARDIOMETABOLIC RISK IN PATIENTS WITH DYSLIPIDEMIA IN THE UK
Caro JJ¹, Getsios D², Proskorovsky I³, Nicholls C⁴, McEwan P^5
1Caro Research Institute, Concord, MA, USA, ²Caro Research Institute, Halifax, NS, Canada, ³Caro Research Institute, Dorval, QC, Canada, ⁴Sanofi-Aventis, Guildford, Surrey, UK, ⁵Cardiff Research Consortium, Cardiff, UK

Methods & Concepts I

MC1
GROWTH, CHARACTERISTICS, AND QUALITY OF THE COST-UTILITY LITERATURE THROUGH 2003 Palmer JA¹, Cohen JT², Cochran GL³, Eldar-Lissai A⁴, Greenberg D⁵, Lavelle TA⁶, Wang ST⁷, Neumann PJ^2
1Tufts-New England Medical Center, Boston, MA, USA, ²Tufts University School of Medicine, Boston, MA, USA, ³University of Nebraska Medical Center, Omaha, NE, USA, ⁴University of Rochester, Rochester, NY, USA, ⁵Ben-Gurion University of the Negev, Beer-Sheva, Israel, ⁶Harvard University, Cambridge, MA, USA, ⁷Harvard School of Public Health, Boston, MA, USA

MC2
15DS – A NEW DYNAMIC QUALITY OF LIFE TOOL WITH INCREASED SENSITIVITY AND IMPROVED COMPOSITE STRUCTURE FOR RECALL BIAS AND RESPONSE SIFT ADJUSTMENTS
Soini EJ¹, Ryynänen OP^2
1Department of Health Policy and Management, Department of Social Pharmacy, University of Kuopio, Kuopio, Finland, ²General Practice, Department of Public Health and Clinical Nutrition, University of Kuopio, Kuopio, Finland

MC3
USING SIMULATIONS TO EXPLORE THE INFLUENCE OF COMPETING RISK ON TREATMENT-EFFECT Kent DM¹, Hayward RA^2
1Tufts-New England Medical Center, Boston, MA, USA, ²University of Michigan, Ann Arbor, MI, USA

MC4
BREAKING THE SILENCE: THE EFFECTS OF EXPLICIT INSTRUCTIONS ON INCORPORATING INCOME IN TTO EXCERCISES
Krol M¹, Brouwer W¹, Sendi P^2
1The Institute for Medical Technology Assessment, Rotterdam, The Netherlands, ²Institute for Clinical Epidemiology, Basel, Switzerland
 

Patient Reported Outcomes

PR1
HEALTH RELATED QUALITY OF LIFE IN DIFFERENT STATES OF BREAST CANCER
Lidgren M¹, Wilking N¹, Jönsson B², Rehnberg C^1
1Karolinska Institutet, Stockholm, Sweden, ²Stockholm School of Economics, Stockholm, Sweden

PR2
ESTIMATING UTILITY VALUES FOR HEALTH STATUS USING THE SPANISH VERSION OF THE SF-36. DATA OF VALIDITY OF THE SF-6D VS EQ-5D IN SPAIN.
Rebollo P¹, Morís J¹, Ortega F², Valdés C^2
1BAP Health Outcomes, Oviedo, Asturias, Spain, ²Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain

PR3
LOW ADHERENCE WITH GASTROPROTECTIVE AGENTS WHEN CO-PRESCRIBED WITH NSNSAIDS ASSOCIATED WITH INCREASING RISK OF GI-RELATED HOSPITALISATION
Koncz T, Lister S, Makinson G
Pfizer Limited, Tadworth, Surrey, UK

PR4
PREFERENCES OF PEOPLE WITH DIABETES FOR INHALED AND INJECTABLE INSULIN REGIMENS Chancellor J¹, Aballéa S¹, Lawrence A², Sheldon R², Cure S¹, Plun-Favreau J^3
1i3 Innovus, Uxbridge, Middlesex, UK, ²Accent, London, UK, ³Pfizer Ltd, Tadworth, UK
 

Schizophrenia

SZ1
Withdrawn

SZ2
TREATMENT PERSISTENCE WITH DIFFERENT ANTIPSYCHOTICS IN PATIENTS WITH SCHIZOPHRENIA Ren X¹, Kazis L², Qian S^22
1Center for Health Quality, Outcomes, and Economic Research, Bedford, MA, USA, ²Boston University, Boston, MA, USA

SZ3
PREDICTORS OF GAF CHANGES IN AUSTRALIANS WITH SCHIZOPHRENIA TREATED WITH RISPERIDONE LONG-ACTING INJECTION (RLAI): INTERIM RESULTS FROM THE E-STAR STUDY Lambert T¹, Emmerson B², Hustig H³, Diels J⁴, Jacobs A⁵, Methven C^6
1The University of Melbourne, Melbourne, Victoria, Australia, ²Royal Brisbane and Women's Hospital, Herston, Queensland, Australia, ³Glenside Hospital, Fullarton, South Australia, Australia, ⁴Janssen Pharmaceutica N.V, Beerse, Belgium, ⁵Janssen Pharmaceutica, Beerse, Belgium, ⁶Janssen-Cilag Pty Ltd, North Ryde, New South Wales, Australia

SZ4
A CARER'S PERSPECTIVE ON THE VALUATION OF SCHIZOPHRENIA-RELATED HEALTH STATES USING THE ASSESSMENT OF QUALITY OF LIFE QUESTIONNAIRE AND THE EQ5D
Adams J¹, Le Reun C¹, Crowley S², Eggleston A^3
1M-TAG Pty Ltd, Chatswood, NSW, Australia, ²Program Evaluation Unit, University of Melbourne; Janssen-Cilag Pty Ltd, North Ryde, NSW, Australia, ³Janssen-Cilag Pty Ltd, North Ryde, NSW, Australia
 

CV5
PHARMACOECONOMIC EVALUATION OF SIMVASTATIN VERSUS “NO TREATMENT” IN PRIMARY AND SECONDARY PREVENTION OF CORONARY HEART DISEASE (CHD) IN POLAND
Plich A¹, Filipiak KJ¹, Splawinski J², Gumulka W^1
1Medical University of Warsaw, Poland, ²National Institute of Public Health, Warsaw, Poland

CV6
DIFFERENCES IN PERCENTAGE LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) REDUCTION AND GOAL ATTAINMENT AMONG NEWLY INITATED USERS OF STATINS IN A REAL LIFE SETTING Heintjes E¹, Hirsch MW², O'Donnell JC², Herings RM^1
1PHARMO Institute, Utrecht, The Netherlands, ²Astra Zeneca UK Ltd, Macclesfield, Cheshire, UK

CV7
RESOURCE UTILIZATION AND COSTS FOLLOWING HOSPITAL INPATIENT ADMISSION FOR CONGESTIVE HEART FAILURE
Gemmen EK¹, Bharmal M¹, Zyczynski T^2
1Quintiles Strategic Research Services, Falls Church, VA, USA, ²GE Healthcare, Princeton, NJ, USA

CV8
REAL WORLD MORTALITY OF THE HYPERTENSIVE PATIENT AS DEFINED IN THE ASCOT-LLA
F Bobadilla J¹, Sicras A², Moreno R³, García Puig J⁴, García M⁵, Navarro R², Soto J^1
1Pfizer Spain, Alcobendas, Madrid, Spain, ²Badalona Servicios Asistenciales, Badalona, Barcelona, Spain, ³San Carlos Clinical Hospital, Madrid, Spain, ⁴La Paz University Hospital, Madrid, Spain, ⁵Euroclin Institute, Alcobendas, Madrid, Spain

Economic Studies II

ES5
RIMONABANT FOR THE TREATMENT OF OVERWEIGHT AND OBESE INDIVIDUALS AT INCREASED CARDIOMETABOLIC RISK: AN ECONOMIC EVALUATION USING DISCRETE EVENT SIMULATION
Getsios D¹, Moller J², Ishak KJ³, McEwan P⁴, Danel A⁵, Caro JJ^6
1Caro Research Institute, Halifax, NS, Canada, ²Caro Research Institute, Eslov, Sweden, ³Caro Research Institute, Montreal, QC, Canada, ⁴Cardiff Research Consortium, Cardiff, UK, ⁵Sanofi-Aventis, Paris Cedex 12, Paris, France, ⁶Caro Research Institute, Concord, MA, USA

ES6
ENTRY AND PRICE RESPONSE IN MARKETS WITHOUT PATENT PROTECTION: THE CASE OF PHARMACEUTICALS IN ARGENTINA
Maceira DA
Center for the Study of the State and Society, Ciudad Autónoma de Buenos Aires, Argentina

ES7
DIRECT MEDICAL COSTS OF STROKE ACCORDING TO HANDICAP LEVELS AFTER 12 AND 18 MONTHS
Bouchez M¹, Jasso Mosqueda G¹, Spieler JF², De Pouvourville G³, Chicoye A¹, Amarenco P^2
1Aremis-aegisnet, Neuilly sur Seine, France, ²Service de Neurologie Hôpital Bichat, Paris, France, ³Gustave Roussy Institute, Villejuif, France

ES8
TREATMENT COSTS OF DIFFERENT PHASES IN BREAST CANCER (BC) IN HUNGARY
Muszbek N¹, Benedict A², Horvath K^3
1UnitedBiosource Corporation, London, United Kingdom, ²UnitedBiosource Corporation, Budapest, Hungary, ³AstraZeneca Hungary, Torokbalint, Hungary

Osteoporosis & Arthritis

OA1
QUALITY OF LIFE IN EARLY RHEUMATOID ARTHRITIS TREATED WITH COMBINATION VS. SINGLE DRUG THERAPY - RESULTS FROM FIN-RACO TRIAL
Hahl J¹, Bergius S¹, Sintonen H², Hannonen P³, Korpela M⁴, Leirisalo-Repo M⁵, Hakala M⁶, Möttönen T^7
1GlaxoSmithKline Oy, Espoo, Finland, ²University of Helsinki, Helsinki, Finland, ³Jyväskylä Central Hospital, Jyväskylä, Finland, ⁴Tampere University Hospital, Tampere, Finland, ⁵Helsinki University Central Hospital, Helsinki, Finland, ⁶Rheumatism Foundation Hospital, Heinola, Finland, ⁷Turku University and Turku University Central Hospital, Paimio, Finland

OA2
SCREENING FOR PATIENTS AT RISK FOR OSTEOPOROSIS BASED ON A RISK-QUESTIONNAIRE IN A GERMAN SETTING OF COMMUNITY PHARMACIES
Lyssy AE¹, Schaefer M^2
1Institut für Klinische Pharmakologie Medizinische Fakultät der Humboldt-Universität/Charité, Berlin, Germany, ²Institut für Klinische Pharmakologie, Berlin, Germany

OA3
HOW DO PRESCRIBERS ACT WHEN A PRODUCT IS WITHDRAWN FROM THE MARKET? FIRST LESSONS FROM THE COX-2 INHIBITORS PATIENTS POST ROFECOXIB STUDY (CIPRES)
Le Pen C, Bergmann JF², Dougados M³, Ruszniewski P⁴, Umuhire D⁵, Chen C⁶, Kramarz P⁷, Lilliu H^7
1Dauphine University, Paris, France, ²Lariboisiere Hospital, Paris, France, ³Cochin Hospital, Paris, France, ⁴Beaujon Hospital, CLICHY Cedex, France, ⁵AREMIS Consultants, Neuilly-sur-seine, France, ⁶Pfizer Inc, New York, NY, USA, ⁷Pfizer, Surrey, UK

OA4
A HEALTH-ECONOMIC EVALUATION OF RHBMP-2 IN SPINE FUSION SURGERY IN GERMANY AND UK
Chhabra A¹, Bentley A², Donnell D¹, Greenberg D³, Oliver E⁴, Alt V^5
1Medtronic Europe Sarl, Tolochenaz, Switzerland, ²Abacus International, Bicester, UK, ³Ben-Gurion University of the Negev, Beer-Sheva, Israel, ⁴Medtronic Ltd, Watford, UK, ⁵University Hospital Giessen-Marburg , Brackenheim, Germany

Respiratory Disorders

RS1
CAN PHARMACEUTICAL INDUSTRY USE REPS TO PROVIDE MEDICAL PRACTICE GUIDELINES? (MIGRAINE AND ASTHMA)
Chaix-couturier C¹, Benis E¹, Calles B², Collomb D¹, Anhoury P^1
1IMS Health, Puteaux, France, ²LIR, Paris, France

RS2
TREATMENT WITH INHALED CORTICOSTEROIDS IN ASTHMA TOO OFTEN DISCONTINUED
Breekveldt-Postma NS¹, Koerselman J¹, Erkens JA¹, Van der Molen T², Lammers JWJ³, Herings RM^1
1PHARMO Institute, Utrecht, The Netherlands, ²University of Groningen, Groningen, The Netherlands, ³University Medical Center Utrecht, Utrecht, The Netherlands

RS3
THE COST-EFFECTIVENESS OF TIOTROPIUM VERSUS IPRATROPIUM IN A US VETERANS POPULATION DIAGNOSED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Akobundu E¹, DeLisle S², Giangreco G³, Mullins CD^1
1University of Maryland School of Pharmacy, Baltimore, MD, USA, ²University of Maryland School of Medicine and VA Maryland Health Care System, Baltimore, MD, USA, ³VA Maryland Health Care System, Baltimore, MD, USA

RS4
CLINICALLY IMPORTANT FACTORS CONTRIBUTING TO COSTS OF CARE DEFINED VIA ANALYSIS OF COMPREHSIVE PATIENT RECORDS
Palmu PJ¹, Reissell E¹, Schultz J¹, Rehn M¹, Pirskanen A¹, Minkkinen S¹, Salonoja M¹, Kunnas T¹, Sintonen H², Haahtela T³, Lindqvist A³, Laitinen T^1
1GeneOS Ltd, Helsinki, Finland, ²University of Helsinki, Helsinki, Finland, ³Helsinki University Hospital, Helsinki, Finland
 

CN1
TREATMENTS FOR METASTATIC MELANOMA: SYNTHESIS OF EVIDENCE FROM RANDOMIZED TRIALS Einarson TR¹, Lui P², Cashin R¹, Machado M³, Corey-Lisle P⁴, Hemels M^5
1University of Toronto, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Universidad de Chile, Santiago, RM, Chile, ⁴Bristol-Myers Squibb, Wallingford, CT, USA, ⁵Bristol-Myers Squibb, Braine-L'Alleud, Belgium

CN2
USING PSYCHOMETRIC AND CLINIMETRIC TECHNIQUES TO SELECT ITEMS FOR USE IN A NEW INSTRUMENT TO MEASURE CANCER-RELATED FATIGUE
Baro E¹, Carulla J², Valentín V³, Rodríguez C⁴, Gascón P⁵, García-Mata J⁶, Colomer R⁷, Cassinello J⁸, Herdman M¹, Gasquet JA⁹, Sánchez J^9
13D Health Research, Barcelona, Spain, ²Hospital de Vall d’Hebrón, Barcelona, Spain, ³Hospital 12 de octubre, Madrid, Spain, ⁴Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ⁵Hospital Clínic i Provincial de Barcelona, Barcelona, Spain, ⁶Hospital Santa Maria Nai, Orense, Spain, ⁷ICO Girona, Girona, Spain, ⁸Hospital Universitario de Guadalajara, Guadalajara, Spain, ⁹AMGEN S.A, Barcelona, Spain

CN3
HARMACOECONOMIC (PE) ANALYSIS OF THE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN THE NETHERLANDS DEMONSTRATES THAT ERLOTINIB DOMINATES DOCETAXEL AND IS COST-EFFECTIVE OVER BEST SUPPORTIVE CARE (BSC) WITHOUT NEED FOR PATIENT STRATIFICATION
Pompen M¹, Novak A¹, Postmus P², Gok M², Gyldmark M^3
1Roche Nederland B.V, Woerden, The Netherlands, ²VU University Medical Center, Amsterdam, The Netherlands, ³F. Hoffmann La Roche, Basel, Switzerland

CN4
COST-EFFECTIVENESS OF ERLOTINIB COMPARED WITH DOCETAXEL FOR THE TREATMENT OF RELAPSED NON-SMALL CELL LUNG CANCER (NSCLC) IN THE UK
Lewis 1, Morlotti L², Creeden J³, Gyldmark M³, Peake MD^4
1Roche Products Limited, Welwyn Garden City, Herts, UK, ²Analytica Int, Loerrach, Germany, ³F Hoffmann La Roche, Basel, Switzerland, ⁴Glenfield Hospital, Leicester, UK

Health Care Use & Policy Studies

HP1
CRITICAL APPRAISAL OF ECONOMIC EVALUATIONS OF CHOLESTEROL LOWERING DRUGS: A SYSTEMATIC REVIEW
Gumbs PD¹, Verschuren WMM², Mantel-Teeuwisse AK¹, De Wit GA², De Boer A¹, Klungel OH^1
1Utrecht University, Utrecht, The Netherlands, ²National Institute for Public Health and the Environment, Bilthoven, The Netherlands

HP2
TRENDS IN ANGIOTENSIN II RECEPTOR BLOCKER (ARB) PRESCRIBING AMONG GENERAL PRACTITIONERS IN THE UK
Blak BT¹, Mullins CD¹, Simoni-Wastila L¹, Shaya FT¹, Cooke CE², Weir MR^1
1University of Maryland, Baltimore, MD, USA, ²Pfizer Inc, Ellicott City, MD, USA

HP3
THE ROLE OF GENERAL PRACTITIONERS IN THE INITIAL MANAGEMENT OF WOMEN WITH URINARY INCONTINENCE IN FRANCE, GERMANY, SPAIN AND THE UK
O' Donnell M¹, Hunskaar S¹, Viktrup L^2
1University of Bergen, Bergen, Norway, ²Eli Lilly and Company, Indianapolis, IN, USA

HP4
SUMMARIZING POPULATION HEALTH USING EQ-5D
Chuang LH, Kind P
University of York, York, UK

Infection

IN1
BUDGETARY IMPACT OF PNEUMOCOCCAL CONJUGATE VACCINATION OF NEWBORNS IN THE PERSPECTIVE OF THE REGIONAL HEALTHCARE SYSTEM OF LOMBARDY
Berto P¹, Principi N^2
1Pbe consulting, Verona, Italy, ²Università di Milano, Fondazione IRCCS “Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena”, Milano, Italy

IN2
EUROPEAN SURVEILLANCE OF ANTIMICROBIAL CONSUMPTION (ESAC): DEVELOPING VALID ANTIBIOTIC PRESCRIBING QUALITY INDICATORS FOR AMBULATORY CARE.
Ferech M, Coenen S, Goossens H
University of Antwerp, Antwerp, Belgium

IN3
RELATIONSHIP BETWEEN ADHERENCE TO ANTIRETROVIRAL THERAPY AND THE COST-EFFECTIVENESS OF ANTIRETROVIRAL THERAPY
Habib MJ¹, Lawson K², Summers KK³, Eakin RT², Barner J², Brown C², Shepherd MD^2
1i3 Innovus, Burlington, ON, Canada, ²University of Texas at Austin, Austin, TX, USA, ³South Texas Veterans Health Care System, San Antonio, TX, USA

IN4
MEDICAL MANAGEMENT AND COSTS ASSOCIATED WITH STAPHYLOCOCCUS AUREUS (SA) BACTERAEMIA IN HAEMODIALYSIS PATIENTS: A COST-OF-ILLNESS STUDY.
Strens D¹, Moeremans K¹, Annemans L¹, Jadoul M², Cambier P³, Billiouw JM^4
1IMS HEOR, Brussels, Belgium, ²Cliniques Universitaires St Luc, Brussels, Belgium, ³CHR Citadelle, Liège,  Belgium, ⁴O.l.Vrouwziekenhuis Aalst, Aalst, Belgium

Methods & Concepts II

MC5
HUMANISTIC BURDEN AND HEALTH RESOURCE UTILIZATION AMONG NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (AMD) PATIENTS: RESULTS FOR GERMANY FROM A MULTI-COUNTRY CROSS-SECTIONAL STUDY
Zlateva G¹, Xu X², Lenz C³, Pauleikhoff D^4
1Pfizer Inc, New York, NY, USA, ²Covance Market Access Services, Gaithersburg, MD, USA, ³Pfizer Pharma GmbH, Germany, Karlsruhe, Germany, ⁴Augenarztpraxis des St. Franziskus-Hospital, Münster, Germany

MC6
HOW DO THE SCORES OF GENERIC HRQOL INSTRUMENTS REFLECT THE DIRECT TTO VALUATIONS OF OWN HEALTH BY GENERAL POPULATION?
Kotomäki T, Honkalampi T, Sintonen H
University of Helsinki, Helsinki, Finland

MC7
TRANSLATION AND VALIDATION OF NEW LANGUAGE VERSIONS OF THE ANKYLOSING SPONDYLITIS QUALITY OF LIFE (ASQOL) QUESTIONNAIRE
Doward LC¹, McKenna SP¹, Meads DM¹, Twiss J¹, Revicki D², Wong R³, Luo MP^4
1Galen Research, Manchester, UK, ²Center for Health Outcomes Research, Bethesda, MD, USA, ³Abbott, Parsippany, NJ, USA, ⁴Abbott, Abbott Park, IL, USA

MC8
THE COST-EFFECTIVENESS OF SMOKING CESSATION INTERVENTIONS. ACCOUNTING FOR MEDICAL COSTS IN LONGER LIFE EXPECTANCIES
Feenstra TL¹, Van Baal P², Hoogenveen R¹, Vijgen SM¹, Bemelmans WJ^3
1National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands, ²National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands, ³National Institute for Public Health and the Environment (RIVM), Bilthoven, Utrecht, The Netherlands
 

17:00-18:00

This forum addresses the general questions of economic evaluation of drug supply at the regional level (with specific examples from some of the regions) and the carrying out of interregional pharmacoeconomics research in Russia. The presentation will be devoted to comparative analysis of several drugs included into reimbursement programs in Russia. Problems concerning the inclusion of expensive drugs and the underlying problems therein will be discussed. The formation of a formulary system in medical institutions, using federal drug lists as basic documents for forming Formulary in the medical institutions, and using the VEN-analysis methodology will also be covered. The forum will then turn to activities of the ISPOR Russia Local Chapter (RSPOR) for the past year.
 

18:00-19:00

20:00-21:30

9th Annual European Congress Main Page